FDA Approves Vera Trutakna, First Dual BAFF/APRIL for IgAN

The FDA granted accelerated approval to Vera Therapeutics’ Trutakna (atacicept-vymj) on July 7, 2026, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Trutakna is the first dual BAFF/APRIL inhibitor approved for IgAN and the sixth drug cleared for the rare kidney disease.

VERA closed at $35.45 on July 23, with a market cap of approximately $2.6 billion. The stock has run roughly 185% over five years, though analyst opinions diverge sharply on whether Trutakna’s market opportunity justifies that valuation.

The ORIGIN 3 data

The approval is based on the Phase 3 ORIGIN 3 trial, which showed a 46% reduction in proteinuria for Trutakna versus placebo. Proteinuria, the presence of excess protein in urine, is a key marker of kidney damage in IgAN. Trutakna is self-administered as a weekly subcutaneous injection via autoinjector, a patient convenience advantage over infused competitors.

The FDA approval notice confirmed the accelerated approval pathway, which requires Vera to submit confirmatory eGFR (estimated glomerular filtration rate) data to convert to full approval. Accelerated approval means the drug is on the market based on a surrogate endpoint, not yet proven to improve long-term kidney function.

What BAFF and APRIL do

IgAN is a progressive kidney disease caused by the buildup of IgA antibodies in the kidney’s filtering units. It affects an estimated 160,000 U.S. patients and is a leading cause of kidney failure. BAFF and APRIL are two cytokines that drive B cells to produce the autoantibodies causing the damage. Trutakna is the first approved drug to block both, attacking the disease upstream at the antibody production stage rather than downstream at the kidney level.

For a framework on evaluating drug mechanisms and clinical endpoints, see our guide to reading a clinical trial press release.

The competitive picture

The IgAN market is now crowded. Travere’s Filspari (sparsentan, an endothelin antagonist), Calliditas’ Tarpeyo (budesonide-targeted release), and Novartis’ Fabhalta (iptacopan, a complement factor B inhibitor) are all approved. Each attacks the disease through a different mechanism.

The competitive question for Trutakna is whether blocking upstream B-cell activation is better than downstream approaches. Endothelin antagonists like Filspari reduce proteinuria by protecting kidney blood vessels. Complement inhibitors like Fabhalta target a specific inflammatory pathway. Trutakna’s dual BAFF/APRIL approach hits the antibody production driving the disease, but enters the market fifth or sixth, not first.

Vertex’s povetacicept, another BAFF/APRIL inhibitor, has a PDUFA date of November 30, 2026. Trutakna has roughly four months of first-mover advantage in the dual-inhibitor class before Vertex arrives.

What to watch next

The risk for Vera investors is the crowded market and the accelerated approval label. Confirmatory eGFR data is required for full approval, and if that data fails to show kidney function benefit, the drug could face withdrawal. Analyst coverage reflects the split: TD Cowen maintains a Buy with a $78 price target, Guggenheim has a $76 Buy, and Wedbush holds a Neutral at $43. The spread between $43 and $78 tells you how much uncertainty exists around Trutakna’s commercial trajectory.

Watch the launch metrics in the first two quarters of 2027. If Trutakna captures meaningful share from Filspari and Tarpeyo, the bull case holds. If payors restrict access or physicians default to entrenched competitors, the $2.6 billion market cap looks rich.

Source: Vera Therapeutics press release | Fierce Pharma